Empagliflozin Scores Topline Win in EMPA-KIDNEY Trial
Researchers stopped the 6600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial of patients with CKD with or without diabetes.
Medscape Medical News
source https://www.medscape.com/viewarticle/970434?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/970434?src=rss
Comments
Post a Comment